# NewAmsterdam Pharma Provides Corporate Update and Reports First Quarter Financial Results
Canonical URL: https://biopharmsignal.com/news/NAMS/newamsterdam-pharma-provides-corporate-update-and-reports-first-quarter-financial-results
Ticker: NAMS
Company: NewAmsterdam Pharma
Source: NewAmsterdam Pharma
Published: 2026-05-07 11:00 EST
Original Source URL: https://ir.newamsterdampharma.com
## Summary

– Decisions on regulatory approval from EMA, UK, and Switzerland for obicetrapib and obicetrapib/ezetimibe fixed - dose combination expected in 2H26, and based on the outcomes, with potential launches by Menarini in 4Q26 in Germany and the UK – – PREVAIL interim analysis planned for 4Q2026 with

## Article Body
– Decisions on regulatory approval from EMA, UK, and Switzerland for obicetrapib and obicetrapib/ezetimibe fixed - dose combination expected in 2H26, and based on the outcomes, with potential launches by Menarini in 4Q26 in Germany and the UK – – PREVAIL interim analysis planned for 4Q2026 with
## Recent Company News
- 2026-07-02 20:01 EST — [NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/NAMS/newamsterdam-pharma-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-3a377d4b) — Source: NewAmsterdam Pharma
- 2026-07-01 12:00 EST — [NewAmsterdam Pharma Announces Upcoming Presentations at the Alzheimer's Association International Conference (AAIC) 2026](https://biopharmsignal.com/news/NAMS/newamsterdam-pharma-announces-upcoming-presentations-at-the-alzheimer-s-associat-5f8e7eb9) — Source: NewAmsterdam Pharma
- 2026-06-03 12:00 EST — [NewAmsterdam Pharma Announces Upcoming Presentations at the National Lipid Association (NLA) 2026 Scientific Sessions](https://biopharmsignal.com/news/NAMS/newamsterdam-pharma-announces-upcoming-presentations-at-the-national-lipid-association-nla-2026-scientific-sessions) — Source: NewAmsterdam Pharma
- 2026-05-28 12:00 EST — [NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in June](https://biopharmsignal.com/news/NAMS/newamsterdam-pharma-to-participate-at-upcoming-investor-conferences-in-june) — Source: NewAmsterdam Pharma
- 2026-05-11 12:41 EST — [NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in May](https://biopharmsignal.com/news/NAMS/newamsterdam-pharma-to-participate-at-upcoming-investor-conferences-in-may) — Source: NewAmsterdam Pharma
## Related News
- 2026-07-21 12:05 EST — VRCA — [Verrica Pharmaceuticals and Medomie Pharma Enter into Exclusive Distribution, Marketing and Supply Agreement to Commercialize YCANTH® for the Treatment of Molluscum Contagiosum in Israel](https://biopharmsignal.com/news/VRCA/verrica-pharmaceuticals-and-medomie-pharma-enter-into-exclusive-distribution-mar-abf61522)
- 2026-07-21 11:30 EST — ABEO — [Cincinnati Children's Activated as the Seventh Qualified Treatment Center for ZEVASKYN®](https://biopharmsignal.com/news/ABEO/cincinnati-children-s-activated-as-the-seventh-qualified-treatment-center-for-ze-8382d043)
- 2026-07-21 10:28 EST — GSK — [ViiV Healthcare to present phase IIIb data comparing Dovato with Biktarvy in treatment-naïve adults alongside INSTI-powered long-acting injectable innovation at AIDS 2026](https://biopharmsignal.com/news/GSK/viiv-healthcare-to-present-phase-iiib-data-comparing-dovato-with-biktarvy-in-tre-1ff3f640)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)